Could Learnings from European Healthcare Markets Apply to the U.S.?

The United States has long faced the difficulty of drug pricing and evaluating the cost-effectiveness of drugs—especially expensive ones. Join us to explore how several European countries use health technology assessment (HTA) agencies to evaluate efficacy and/or cost-effectiveness, and how the U.S. might be able to replicate these methods to solve its drug valuation crisis.